NKGen Biotech ( (NKGN) ) has released a notification of late filing.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NKGen Biotech, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for this delay is the additional time required for the valuation and review of various derivative securities, as the company has taken on more internal reporting responsibilities. Furthermore, NKGen is concurrently working on completing its Annual Report on Form 10-K (Yearly Report) for the fiscal year ending December 31, 2024. The company anticipates filing the delayed report within five calendar days following the prescribed due date. Despite the delay, NKGen does not expect any significant changes in its financial results compared to the previous year’s corresponding period. The company remains committed to compliance, with the notification signed by CEO Paul Song.
More about NKGen Biotech
Average Trading Volume: 2,424,957
Technical Sentiment Signal: Sell
Current Market Cap: $13.03M
See more data about NKGN stock on TipRanks’ Stock Analysis page.